Search results
Results from the WOW.Com Content Network
This is a list of psychiatric medications used by psychiatrists and other physicians to treat mental illness or distress. The list is ordered alphabetically according to the condition or conditions, then by the generic name of each medication. The list is not exhaustive and not all drugs are used regularly in all countries.
This is a complete list of clinically approved prescription antidepressants throughout the world, as well as clinically approved prescription drugs used to augment antidepressants or mood stabilizers, by pharmacological and/or structural classification. Chemical/generic names are listed first, with brand names in parentheses.
Escitalopram, sold under the brand names Lexapro and Cipralex, among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. [9] Escitalopram is mainly used to treat major depressive disorder and generalized anxiety disorder. [9]
Paroxetine was the first drug to be approved for social anxiety disorder and it is considered effective for this disorder; sertraline and fluvoxamine were later approved for it as well. Escitalopram and citalopram are used off-label with acceptable efficacy, while fluoxetine is not considered to be effective for this disorder. [ 22 ]
Keppra (levetiracetam) – an anticonvulsant drug which is sometimes used as a mood stabilizer and has potential benefits for other psychiatric and neurologic conditions such as Tourette syndrome, anxiety disorder, and Alzheimer's disease; Klonopin – anti-anxiety and anti-epileptic medication of the benzodiazepine class
weakness, or anxiety Large dose: loss of consciousness Perfluoroisobutene Gas: colorless Odor: none 1-4 hours Flu-like, also eye, nose, and throat irritation, and chest discomfort, or no symptoms Phosgene Gas: colorless Odor: decaying fruit, fresh-cut grass, 1-4 hours; small doses, 24-48 hours Burning eyes, sore throat, dry
The effects of antidepressants typically do not continue once the course of medication ends. This results in a high rate of relapse. In 2003, a meta-analysis found that 18% of people who had responded to an antidepressant relapsed while still taking it, compared to 41% whose antidepressant was switched for a placebo. [116]
“You got all these people with this disease who need treatment,” he said. “There’s a medication that could really help us tackle this problem, help us dramatically reduce overdose death, and people are having a hard time accessing it.” The anti-medication approach adopted by the U.S. sets it apart from the rest of the developed world.